Enanta Pharmaceuticals (ENTA) Revenue (2012 - 2026)

Enanta Pharmaceuticals' Revenue history runs 15 years deep, the most recent figure standing at $17.2 million for Q1 2026.

• Quarterly Revenue rose 14.96% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.2 million (up 7.37% YoY) and the FY2025 annual result came in at $65.3 million, down 3.42% from the prior year.
• Revenue was $17.2 million for Q1 2026 at Enanta Pharmaceuticals, down from $18.6 million in the prior quarter.
• Across five years, Revenue topped out at $23.6 million in Q4 2022 and bottomed at $14.6 million in Q3 2024.
• A 5-year average of $18.0 million and a median of $18.0 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue decreased 23.67% — and 2026, when it rose 14.96%.
• Enanta Pharmaceuticals' Revenue stood at $23.6 million in 2022, then dropped by 23.67% to $18.0 million in 2023, then slipped by 5.8% to $17.0 million in 2024, then climbed by 9.76% to $18.6 million in 2025, then decreased by 7.82% to $17.2 million in 2026.
• Business Quant data shows ENTA's Revenue at $17.2 million in Q1 2026, $18.6 million in Q4 2025, and $15.1 million in Q3 2025.